SAN DIEGO—(BUSINESS WIRE)—Nov. 4, 2004—ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report third quarter 2004 financial results on Wednesday, November 10, 2004, after the U.S. financial markets close.
ACADIA will host a conference call and webcast on Wednesday, November 10, 2004 at 4:30 p.m. EST to discuss financial results for the third quarter ended September 30, 2004. Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer, will also provide an update on the Company's progress.
The conference call may be accessed by dialing 800-901-5247 for participants from the United States or Canada and 617-786-4501 for international callers (reference participant passcode 92945056). The conference call will also be webcast live on ACADIA's website at www.acadia-pharm.com, under the investor relations section, and will be archived there until November 24, 2004.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five drug programs in clinical and preclinical development directed at large unmet medical needs and major commercial markets, including Parkinson's disease, schizophrenia, chronic pain, and glaucoma. Using its proprietary drug discovery platform, ACADIA has discovered all of the drug candidates in its product pipeline. ACADIA's corporate headquarters and biology research facilities are located in San Diego, California and its chemistry research facilities are located near Copenhagen, Denmark.
CONTACT: ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, 858-558-2871